



# 2026 Q1 Trading Update

16 April 2026

These written materials or the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful or require registration or any other measure and does not constitute an offer of securities for sale in such countries.

# Today's presenters



Walter Hess  
CEO



Daniel Wüest  
CFO

# Agenda

1. Q1 Trading Update
2. Q&A



# Highlights Q1 2026: Strong start into the year confirming guidance 2026



Strong revenue growth of **10.7% yoy**



**30.4% Rx growth yoy** and **7.6% qoq** with acceleration in March



Digital Services with growth of **63.1%** alongside **increasing margins**




Active customers grew by **1.0m yoy** to **12.6m** and **0.4m qoq**



On track to EBITDA breakeven: adj. EBITDA of **CHF -6m** plus **CHF 10m yoy**

# Sustained quarterly Rx revenue growth with acceleration in Q1 2026




Indicative revenue split | 1 PKV = private Krankenversicherung (private health insurance in Germany) | 2 GKV = gesetzliche Kranken- und Pflegekassen (public health and care insurance in Germany)



All financial data in this presentation is unaudited

# Non-Rx business drives value by continuously delivering profitable growth



1 External revenue segment Germany


## OTC/BPC

- 4.4% OTC revenue growth according to plan
- Strong basis for Retail Media business

## Digital Services

- Teleclinic and Retail Media together with Marketplace grew by 63.1%
- Providing continuously growing profit contribution

# Well on track towards EBITDA breakeven in the course of 2026



- Ongoing adj. EBITDA improvement since Q1 2025 driven by
  - strong operational performance
  - enhanced marketing efficiency
  - disciplined cost management
- CHF -6.3m adj. EBITDA in Q1 2026 representing an improvement of CHF 9.8m compared to Q1 2025
- Adj. EBITDA margin<sup>1</sup> increased by 360 bps to -2.1% yoy

Chart indicative

<sup>1</sup> Based on revenue in CHF

# Short- and mid-term outlook fully confirmed

External revenue <sup>1</sup> 2026 in local currency	Mid-single digit to low teens
Adj. EBITDA 2026	CHF -10m to - 25m
Capital expenditure 2026	CHF ~30m

EBITDA breakeven in the course of 2026 and positive free cashflow in the course of 2027

External revenue <sup>1</sup> mid-term	~15% CAGR <sup>2</sup> (back-end loaded due to increasing relative weight of Rx and Digital Services)
EBITDA margin mid-term	~8%
Capital expenditure mid-term	CHF ~30m (p.a.)

Guidance subject to stable regulatory environment | 1 External revenue consists of the consolidated revenue of DocMorris and apotal | 2 CAGR = compounded annual growth rate

# Proposed Board Nominees standing for expertise and independence



**Prof. Dr. Andréa Belliger**  
Member Digital Health



**Walter Oberhänsli**  
Chairman & Founder



**Florian Seubert**  
Member E-commerce

## Board Nominees



**Thomas Bucher**  
Nominee Finance,  
Capital Markets



**Nicole Formica-Schiller**  
Nominee Regulatory, AI  
Health



**Dr. Thomas U. Reutter**  
Nominee Governance,  
Legal

- Existing members guarantee stability and continuity to execute strategy
- Highly credible, independent Board Nominees bringing deep expertise in
  - AI & Digital Health
  - Regulatory DE & EU
  - Governance
  - Capital Markets
- All new Nominees are independent and aligned with all shareholders' interests

# Q&A

# Financial calendar

Date	Event/publication
12 May 2026	Annual General Meeting 2026
19 August 2026	H1 2026 Results (incl. conference call)
15 October 2026	Q3 2026 Trading Update
4th quarter 2026	Capital Markets Day

Thank you



# Disclaimer

This presentation (the "Presentation") has been prepared by DocMorris AG ("DocMorris" and together with its subsidiaries, "we", "us" or "DocMorris") solely for informational purposes and has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of any of DocMorris. DocMorris reserves the right to amend or replace the Presentation at any time and undertakes no obligation to provide the recipients with access to any additional information. DocMorris shall not be obligated to update or correct the information set forth in the Presentation or to provide any additional information. Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future.

Certain statements in this Presentation are forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which DocMorris operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other

conditions affecting DocMorris' markets, and other factors beyond the control of DocMorris). Neither DocMorris nor any of its respective directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this Presentation. Statements contained in this Presentation regarding past trends or events should not be taken as a representation that such trends or events will continue in the future.

This Presentation does not constitute or form part of, and should not be construed as, an offer or invitation or inducement to subscribe for, underwrite or otherwise acquire, any securities of DocMorris, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of DocMorris, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. This Presentation is not a prospectus and is being made available to you solely for your information and background and is not to be used as a basis for an investment decision in securities of DocMorris.